Drug companies AstraZeneca and Pfizer are being attacked by the EU over vaccine delivery delays that could slow the EU’s recovery from Covid-19, says Julia Horowitz on CNN. Pfizer’s problems look likely to be resolved soon, however, while AstraZeneca says “considerably fewer” doses will be supplied for some time. With AstraZeneca’s jab due to be approved by Europe’s regulator shortly, “mounting” anger means that Brussels and several countries are “threatening to take legal action and introduce export controls on doses produced in the bloc” (see page 8).
AstaZeneca’s announcement will prolong the “misery and pain” of Covid-19, says Aimee Donnellan on Breakingviews. Still, problems were “inevitable” as the vaccine, developed by the University of Oxford, is made “through a complicated biological process, requiring constant fine-tuning and vast 4,000-litre fermenters, which are in short supply”.
AstraZeneca’s problems are good news for the jab produced by Janssen, Johnson & Johnson’s European vaccine division, which the EU has pre-ordered in large amounts, says the Irish Times. Like the AstraZeneca jab, it doesn’t require “ultra-cold storage temperatures”; but unlike all its major competitors, it also involves a single injection, “greatly simplifying... a national vaccine rollout”. With trial data expected in the next few days, the vaccine is set to receive approval from the US Food and Drug Administration sometime in February, with the nod from the European Medicines Agency expected not long afterwards.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
The ‘invisible’ millions: banking’s new frontierFrom microloans for farmers to insurance for gig workers, Baillie Gifford’s Ed Whitten discusses the high-impact financial firms with great growth potential.
-
How much do parents have saved for their children where you live?Parents amass thousands of pounds to give their children an advantage when getting onto the property ladder or paying for higher education – but the average amount varies across different regions
-
Are wealthy whisky enthusiasts leaving Britain?Collectables Wealthy whisky enthusiasts are heading to tax-friendly countries such as Dubai, where there is more disposable income to spend on collectable luxuries like rare whisky.
-
'The rise and fall of Kodak is a lesson for the tech giants'Opinion The long decline of Kodak – a once-dominant company – shows why no business is safe from disruption, says Matthew Lynn
-
8 of the best properties for sale with kitchen gardensThe best properties for sale with kitchen gardens – from a 17th-century timber-framed hall house in Norfolk, to an Arts & Crafts house in West Sussex designed by Charles Voysey with a garden by Gertrude Jekyll
-
Why investors can no longer trust traditional statistical indicatorsOpinion The statistical indicators and data investors have relied on for decades are no longer fit for purpose. It's time to move on, says Helen Thomas
-
Investors rediscover the virtue of value investing over growthGrowth investing, betting on rapidly expanding companies, has proved successful since 2008. But now the other main investment style seems to be coming back into fashion.
-
8 of the best properties for sale with shooting estatesThe best properties for sale with shooting estates – from an estate in a designated Dark Sky area in Ayrshire, Scotland, to a hunting estate in Tuscany with a wild boar, mouflon, deer and hare shoot
-
What we can learn from Britain’s "Dashing Dozen" stocksStocks that consistently outperform the market are clearly doing something right. What can we learn from the UK's top performers and which ones are still buys?
-
The most likely outcome of the AI boom is a big fallOpinion Like the dotcom boom of the late 1990s, AI is not paying off – despite huge investments being made in the hope of creating AI-based wealth
